Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ankylosing spondylitis
Pharma
Trial win sets up AbbVie's Rinvoq up for likely Crohn's approval
A phase 3 trial of AbbVie's Rinvoq shows it to be effective as a maintenance treatment for Crohn’s disease, setting it up for a likely FDA approval.
Kevin Dunleavy
May 12, 2022 9:52am
AbbVie's red-hot Rinvoq picks up 4th FDA nod in 5 months
Apr 29, 2022 5:05pm
AbbVie says Rinvoq, Skyrizi combined will outperform Humira
Jan 11, 2022 6:15pm
AbbVie's Rinvoq hunts for ankylosing spondylitis nods in EU, US
Jan 10, 2022 9:50am
AbbVie's Rinvoq, Pfizer's Xeljanz nab JAK label expansions
Dec 15, 2021 10:58am
Analysts pick apart JAKs' potential in various indications
Sep 13, 2021 11:41am